tetano
Editor, Senior Moderator
Vaccine
. 2020 Jul 29;S0264-410X(20)30935-X.
doi: 10.1016/j.vaccine.2020.07.022. Online ahead of print.
Inactivated influenza vaccine formulated with single-stranded RNA-based adjuvant confers mucosal immunity and cross-protection against influenza virus infection
Yun-Hee Kim[SUP] 1 [/SUP], Yoo-Jin Bang[SUP] 2 [/SUP], Hyo-Jung Park[SUP] 2 [/SUP], Hae Li Ko[SUP] 3 [/SUP], Sang-In Park[SUP] 4 [/SUP], Kyung-Ah Hwang[SUP] 5 [/SUP], Hun Kim[SUP] 6 [/SUP], Jae-Hwan Nam[SUP] 7 [/SUP]
Affiliations
Abstract
Influenza vaccination is considered the most valuable means to prevent and control seasonal influenza infections, which causes various clinical symptoms, ranging from mild cough and fever to even death. Among various influenza vaccine types, the inactivated subunit type is known to provide improved safety with reduced reactogenicity. However, there are some drawbacks associated with inactivated subunit type vaccines, with the main ones being its low immunogenicity and the induction of Th2-biased immune responses. In this study, we investigated the role of a single-stranded RNA (ssRNA) derived from the intergenic region in the internal ribosome entry site of the Cricket paralysis virus as an adjuvant rather than the universal vaccine for a seasonal inactivated subunit influenza vaccine. The ssRNA adjuvant stimulated not only well-balanced cellular (indicated by IgG2a, IFN-γ, IL-2, and TNF-α) and humoral (indicated by IgG1 and IL-4) immune responses but also a mucosal immune response (indicated by IgA), a key protector against respiratory virus infections. It also increases the HI titer, the surrogate marker of influenza vaccine efficacy. Furthermore, ssRNA adjuvant confers cross-protective immune responses against heterologous influenza virus infection while promoting enhanced viral clearance. Moreover, ssRNA adjuvant increases the number of memory CD4[SUP]+[/SUP] and CD8[SUP]+[/SUP] T cells, which can be expected to induce long-term immune responses. Therefore, this ssRNA-adjuvanted seasonal inactivated subunit influenza vaccine might be the best influenza vaccine generating robust humoral and cellular immune responses and conferring cross-protective and long-term immunity.
Keywords: Cross-protective immune response; Inactivated influenza vaccine; Mucosal immunity; RNA adjuvant.
. 2020 Jul 29;S0264-410X(20)30935-X.
doi: 10.1016/j.vaccine.2020.07.022. Online ahead of print.
Inactivated influenza vaccine formulated with single-stranded RNA-based adjuvant confers mucosal immunity and cross-protection against influenza virus infection
Yun-Hee Kim[SUP] 1 [/SUP], Yoo-Jin Bang[SUP] 2 [/SUP], Hyo-Jung Park[SUP] 2 [/SUP], Hae Li Ko[SUP] 3 [/SUP], Sang-In Park[SUP] 4 [/SUP], Kyung-Ah Hwang[SUP] 5 [/SUP], Hun Kim[SUP] 6 [/SUP], Jae-Hwan Nam[SUP] 7 [/SUP]
Affiliations
- PMID: 32739118
- DOI: 10.1016/j.vaccine.2020.07.022
Abstract
Influenza vaccination is considered the most valuable means to prevent and control seasonal influenza infections, which causes various clinical symptoms, ranging from mild cough and fever to even death. Among various influenza vaccine types, the inactivated subunit type is known to provide improved safety with reduced reactogenicity. However, there are some drawbacks associated with inactivated subunit type vaccines, with the main ones being its low immunogenicity and the induction of Th2-biased immune responses. In this study, we investigated the role of a single-stranded RNA (ssRNA) derived from the intergenic region in the internal ribosome entry site of the Cricket paralysis virus as an adjuvant rather than the universal vaccine for a seasonal inactivated subunit influenza vaccine. The ssRNA adjuvant stimulated not only well-balanced cellular (indicated by IgG2a, IFN-γ, IL-2, and TNF-α) and humoral (indicated by IgG1 and IL-4) immune responses but also a mucosal immune response (indicated by IgA), a key protector against respiratory virus infections. It also increases the HI titer, the surrogate marker of influenza vaccine efficacy. Furthermore, ssRNA adjuvant confers cross-protective immune responses against heterologous influenza virus infection while promoting enhanced viral clearance. Moreover, ssRNA adjuvant increases the number of memory CD4[SUP]+[/SUP] and CD8[SUP]+[/SUP] T cells, which can be expected to induce long-term immune responses. Therefore, this ssRNA-adjuvanted seasonal inactivated subunit influenza vaccine might be the best influenza vaccine generating robust humoral and cellular immune responses and conferring cross-protective and long-term immunity.
Keywords: Cross-protective immune response; Inactivated influenza vaccine; Mucosal immunity; RNA adjuvant.